Guggenheim raised the firm’s price target on Sionna Therapeutics (SION) to $50 from $45 and keeps a Buy rating on the shares after the company announced FY25 earnings. The firm continues to believe that Sionna has the potential to “revolutionize the cystic fibrosis treatment paradigm with its first-in-class NBD1 stabilizers,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics files automatic mixed securities shelf
- Sionna Therapeutics reports Q4 EPS (46c), consensus (55c)
- Sionna Therapeutics initiated with an Outperform at Citizens
- Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target
- Sionna Therapeutics price target raised to $58 from $50 at BTIG